Collegium Pharmaceutical Inc (COLL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Collegium Pharmaceutical Inc (COLL) has a cash flow conversion efficiency ratio of 0.285x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($78.44 Million) by net assets ($274.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check COLL strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Collegium Pharmaceutical Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Collegium Pharmaceutical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See net assets of Collegium Pharmaceutical Inc for net asset value and shareholders' equity analysis.
Collegium Pharmaceutical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Collegium Pharmaceutical Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Total Gabon
F:RZW
|
0.045x |
|
Universal Insurance Holdings Inc
NYSE:UVE
|
0.265x |
|
Healthcare Global Enterprises Limited
NSE:HCG
|
0.193x |
|
Beijing Kingee Culture Development Co Ltd
SHE:002721
|
0.000x |
|
EcoRodovias Infraestrutura e Logística S.A
SA:ECOR3
|
0.312x |
|
Tekla Healthcare Investors
NYSE:HQH
|
0.008x |
|
Lingda Group Co Ltd
SHE:300125
|
-0.021x |
|
LS Materials
KQ:417200
|
0.016x |
Annual Cash Flow Conversion Efficiency for Collegium Pharmaceutical Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Collegium Pharmaceutical Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Collegium Pharmaceutical Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $228.84 Million | $204.98 Million | 0.896x | -36.29% |
| 2023-12-31 | $195.43 Million | $274.75 Million | 1.406x | +120.50% |
| 2022-12-31 | $194.84 Million | $124.23 Million | 0.638x | +24.94% |
| 2021-12-31 | $202.93 Million | $103.56 Million | 0.510x | +1.06% |
| 2020-12-31 | $186.03 Million | $93.94 Million | 0.505x | +58.92% |
| 2019-12-31 | $87.43 Million | $27.78 Million | 0.318x | -82.82% |
| 2018-12-31 | $91.58 Million | $169.39 Million | 1.850x | +387.24% |
| 2017-12-31 | $104.08 Million | $-67.02 Million | -0.644x | -15.74% |
| 2016-12-31 | $134.91 Million | $-75.05 Million | -0.556x | -119.45% |
| 2015-12-31 | $85.07 Million | $-21.57 Million | -0.254x | -117.29% |
| 2014-12-31 | $-12.24 Million | $-17.95 Million | 1.466x | +149.51% |
| 2013-12-31 | $5.58 Million | $-16.53 Million | -2.961x | -- |
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine… Read more